DOI: https://doi.org/10.14710/dimj.v3i2.15219

The Effect of Folic Acid Adjuvant on Cognitive Function on Patients with Chronic Schizophrenia

*Yulia Ratna Sofa  -  Department of Psychiatry, Faculty of Medicine, Diponegoro University, Indonesia, Indonesia
Natalia Dewi Wardani orcid  -  Department of Psychiatry, Faculty of Medicine, Diponegoro University, Indonesia, Indonesia
Linda Kartika sari  -  , Indonesia
Titis Hadiati  -  , Indonesia
Open Access Copyright (c) 2022 Diponegoro International Medical Journal
Creative Commons License This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Citation Format:
Abstract

ABSTRACT  

 

Background: Schizophrenia is a severe mental disorder that associated with daily life and social function deterioration and could be accompanied with cognitive deficits. Meanwhile, hyperhomocysteinemia (HHcy) is the increasing homocysteine (Hcy) level which might be the one of biological factor in schizophrenia. In recent study with healthy subjects, it was known that there was a correlation between total Hcy level and cognitive function. Folic acid is part of water-soluble vitamin B and expected to have important role in oxidative stress by preventing hyperhomocysteinemia.

Objective: This study aimed to elaborate the effect of folic acid adjuvant to improve cognitive function in chronic schizophrenia patients.

Methods: This was a double-blinded randomized controlled trial with pre and post-test clinical trial design. This study included 32 patients in control group and 32 patients in treatment group. MOCA-INA score was examined in all subjects on the first day. Then, all subjects were given standard antipsychotic treatment plus folic acid adjuvant / placebo during 3 week of hospitalized treatment and 1 week of outpatient treatment. When the 4-week treatment finished, the subjects were followed by MOCA-INA post-test.

Results: In this study, we had the significant difference of pre and post-test MOCA-INA score in the control group (p<0.001), significant difference of pre and post-test MOCA-INA score in the treatment group (p<0.001), and significant difference of post-test MOCA-INA score between the control and treatment group (p<0.001).

Conclusion: Folic acid adjuvants significantly improved cognitive function in chronic schizophrenic patients.

 

 

Fulltext View|Download
Keywords: chronic schizophrenia, folic acid, cognitive function

Article Metrics:

Article Info
Section: Original Research Article
Language : EN
Recent articles
Factors Associated With Recurrence Of Epithelial Ovarian Cancer In RSUP Dr. Kariadi Semarang A Comparison of Wound Healing Score between Chromic Catgut and Polyglycolic Acid Perineal Suturing at Seven Days Postpartum: A Single Blind Randomized Controlled Trial The Effect of Folic Acid Adjuvant on Cognitive Function on Patients with Chronic Schizophrenia More recent articles
  1. James Sadock Benjamin, Virginia Alcott Sadock PRM. Schizophrenia. In: Synopsis Of Psychiatry. 2015
  2. Kementrian Kesehatan RI 2018. Hasil Utama Riskesdas 2018. https://www.kemkes.go.id/
  3. Torniainen, M. Cognitive Impairment in Schizophrenia : Related Risk Factors and Clinical Characteristics. Academic dissertation published. Finlandia : National institute for health and welfare; 2013. p. 22-23
  4. Penades, R., Catalan, R. Cognitive Remediation Theraphy (CRT) : improving neurocognition and functioning in schizophrenia. Journal of Psychiatry; 2012 ; P. 1-19
  5. Moustafa AA, Hewedi DH, Eissa AM, Frydecka D, Misiak B. Homocysteine levels in schizophrenia and affective disorders—focus on cognition. Front Behav Neurosci. 2014; 8(OCT):1–10
  6. Krebs MO, Bellon A, Mainguy G, Jay TM, Frieling H. One-carbon metabolism and schizophrenia : current challenges and future directions. Trends Mol Med. 2009;15(12):562–70
  7. Abd SM, Mawella E, Hussein HA, Ahmed T. Folate, vitamin B 12 and negative symptoms in schizophrenia. 2018; 89–94
  8. Zugno AI, Canever L, Heylmann AS, Wessler PG, Steckert A, Mastella GA, et al. Effect of folic acid on oxidative stress and behavioral changes in the animal model of schizophrenia induced by ketamine. J Psychiatr Res [Internet]. 2016; 81:23–35
  9. Enderami A. The effects and potential mechanisms of folic acid on cognitive function : a comprehensive review. 2018
  10. Torniainen M. Cognitive Impairment in Schizophrenia : Related Risk Factors and Clinical Characteristics. National Institute for Health and Welfare; 2013
  11. Filatova S, Marttila R, Koivumaa-Honkanen H, et al. A comparison of the cumulative incidence and early risk factors for psychotic disorder in young adults in the Northern Finland Birth Cohorts 1966 and 1986. Epidemiol Psychiatr Sci. 2017;26(3):314-324. doi: 10.1017/S2045796016000123
  12. Hakulinen C, McGrath JJ, Timmerman A, et al. The association between early-onset schizophrenia with employment, income, education, and cohabitation status: nationwide study with 35 years of follow-up. Soc Psychiatry Psychiatr Epidemiol. 2019;54(11):1343-1351. doi: 10.1007/s00127-019-01756-0
  13. Ran MS, Xiao Y, Zhao X, et al. Family history of psychosis and outcome of people with schizophrenia in rural China: 14-year follow-up study. Asian J Psychiatr. 2018;32(December 2017):14-19. doi: 10.1016/j.ajp.2017.11.016
  14. Bergen SE, O’Dushlaine CT, Lee PH, et al. Genetic modifiers and subtypes in schizophrenia: Investigations of age at onset, severity, sex and family history. Schizophr Res. 2014;154(1-3):48-53. doi: 10.1016/j.schres.2014.01.030
  15. Husein N, Lumempouw N, Ramli Y, Herqutanto. Uji validitas san reabilitas montreal cognitive assessment versi Indonesia (MoCA-Ina) untuk skrining gangguan kognitif. Available from http://mru.fk.ui.ac.id. Accessed on September 2016
  16. Tripathi A, Kar SK, Shukla R. Cognitive deficits in schizophrenia: Understanding the biological correlates and remediation strategies. Clin Psychopharmacol Neurosci. 2018;16(1):7-17. doi: 10.9758/cpn.2018.16.1.7
  17. Madireddy S, Madireddy S. Regulation of reactive oxygen species‐mediated damage in the pathogenesis of schizophrenia. Brain Sci. 2020;10(10):1-24. doi: 10.3390/brainsci10100742
  18. Ma F, Wu T, Zhao J, et al. Folic acid supplementation improves cognitive function by reducing the levels of peripheral inflammatory cytokines in elderly Chinese subjects with MCI. Sci Rep. 2016;6(March):1-11. doi: 10.1038/srep37486
  19. Brown HE, Roffman JL. Vitamin supplementation in the treatment of schizophrenia. CNS Drugs. 2014;28(7):611-622. doi: 10.1007/s40263-014-0172-4
  20. Numata S, Kinoshita M, Tajima A, Nishi A, Imoto I, Ohmori T. Evaluation of an association between plasma total homocysteine and schizophrenia by a Mendelian randomization analysis. BMC Med Genet. 2015;16(1). doi: 10.1186/s12881-015-0197-7
  21. Moustafa AA, Hewedi DH, Eissa AM, Frydecka D, Misiak B. Homocysteine levels in schizophrenia and affective disorders—focus on cognition. Front Behav Neurosci. 2014;8(OCT):1-10. doi: 10.3389/fnbeh.2014.00343
  22. Hsu WY, Lane HY, Lin CH. Medications used for cognitive enhancement in patients with schizophrenia, bipolar disorder, Alzheimer’s disease, and Parkinson’s disease. Front Psychiatry. 2018;9(APR). doi: 10.3389/fpsyt.2018.00091
  23. Zhou Z, Zhu Y, Wang J, Zhu H. Risperidone improves interpersonal perception and executive function in patients with schizophrenia. Neuropsychiatr Dis Treat. 2017;13:101-107. doi: 10.2147/NDT.S120843

Last update:

No citation recorded.

Last update:

No citation recorded.